FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma By Ogkologos - May 20, 2026 114 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context May 22, 2026 FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο February 22, 2020 Latest Data Indicate New Care Standard in Advanced/Recurrent Endometrial Cancer: Results... March 27, 2023 Penn State Researchers Working on Amazon Alexa Skill for Metastatic Breast... May 4, 2021 Load more HOT NEWS Addressing Mental Health Needs of Adolescent and Young Adult Cancer Survivors Tailored Radiation to Treat Brain Metastases Reduces Impact on Cognitive Function FDA Approves Bosutinib for Paediatric Patients with Chronic Myelogenous Leukaemia COVID-19 Vaccines May Be Less Effective in Some People with Cancer
